0001628280-24-027351.txt : 20240607 0001628280-24-027351.hdr.sgml : 20240607 20240607182935 ACCESSION NUMBER: 0001628280-24-027351 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240605 FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Williams Laura A CENTRAL INDEX KEY: 0001869194 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36485 FILM NUMBER: 241031047 MAIL ADDRESS: STREET 1: 116 HUNTINGTON AVENUE, 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARDELYX, INC. CENTRAL INDEX KEY: 0001437402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 510-745-7047 MAIL ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: NTERYX INC DATE OF NAME CHANGE: 20080611 4 1 wk-form4_1717799368.xml FORM 4 X0508 4 2024-06-05 0 0001437402 ARDELYX, INC. ARDX 0001869194 Williams Laura A C/O ARDELYX, INC. 400 FIFTH AVENUE, SUITE 210 WALTHAM MA 02451 0 1 0 0 Chief Medical Officer 0 Common Stock 2024-06-05 4 M 0 100000 2.75 A 467152 D Common Stock 2024-06-05 4 S 0 45000 7.124 D 422152 D Common Stock 2024-06-05 4 S 0 100000 7.125 D 322152 D Stock Option (Right to Buy) 2.75 2024-06-05 4 M 0 100000 0 D 2033-01-05 Common Stock 100000 251000 D This transaction was executed in multiple trades in prices ranging from $7.11 to $7.145, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. /s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams 2024-06-07